皮肤癣菌感染

Ameen M, Lear JT, Madan V, et al. British Association of Dermatologists' guidelines for the management of onychomycosis 2014. Br J Dermatol. 2014;171:937-958.

• 全文
• 摘要

Fuller LC, Barton RC, Mohd Mustapa MF, et al. British Association of Dermatologists’ guidelines for the management of tinea capitis 2014. Br J Dermatol. 2014;171:454-463.

• 全文
• 摘要

1.  Gupta AK, Jain HC, Lynde CW, et al. Prevalence and epidemiology of unsuspected onychomycosis in patients visiting dermatologists' offices in Ontario, Canada - a multicenter survey of 2001 patients. Int J Dermatol. 1997;36:783-787.

• 摘要

2.  Drake LA, Dinehart SM, Farmer ER, et al. Guidelines of care for superficial mycotic infections of the skin: tinea corporis, tinea cruris, tinea faciei, tinea manuum, and tinea pedis. Guidelines/Outcomes Committee. American Academy of Dermatology. J Am Acad Dermatol. 1996;34:282-286.

• 摘要

3.  Faergemann J, Baran R. Epidemiology, clinical presentation and diagnosis of onychomycosis. Br J Dermatol. 2003;149(suppl 65):1-4.

• 摘要

4.  Macura AB. Dermatophyte infections. Int J Dermatol. 1993:32:313-323.

• 摘要

5.  National Association of State Public Health Veterinarians; Centers for Disease Control and Prevention. Compendium of measures to prevent disease associated with animals in public settings, 2013. J Am Vet Med Assoc. 2013;243:1270-1288.

• 全文
• 摘要

6.  Ameen M, Lear JT, Madan V, et al. British Association of Dermatologists' guidelines for the management of onychomycosis 2014. Br J Dermatol. 2014;171:937-958.

• 全文
• 摘要

7.  Fuller LC, Barton RC, Mohd Mustapa MF, et al. British Association of Dermatologists’ guidelines for the management of tinea capitis 2014. Br J Dermatol. 2014;171:454-463.

• 全文
• 摘要

8.  Gupta AK, Drummond-Main C, Cooper EA, et al. Systematic review of nondermatophyte mold onychomycosis: diagnosis, clinical types, epidemiology, and treatment. J Am Acad Dermatol. 2012;66:494-502.

• 摘要

9.  Miteva M, Tosti A. Hair and scalp dermatoscopy. J Am Acad Dermatol. 2012;67:1040-1048.

• 摘要

10.  Spiliopoulou A, Bartzavali C, Jelastopulu E, et al. Evaluation of a commercial PCR test for the diagnosis of dermatophyte nail infections. J Med Microbiol. 2015;64:25-31.

• 摘要

11.  Rotta I, Sanchez A, Gonçalves PR, et al. Efficacy and safety of topical antifungals in the treatment of dermatomycosis: a systematic review. Br J Dermatol. 2012;166:927-933.

• 摘要

12.  Chang, CH, Young-Xu Y, Kurth T, et al. The safety of oral antifungal treatments for superficial dermatophytosis and onychomycosis: a meta-analysis. Am J Med. 2007;120:791-798.

• 摘要

13.  Gupta AK, Cooper EA, Bowen JE, et al. Meta-analysis: griseofulvin efficacy in the treatment of tinea capitis. J Drugs Dermatol. 2008;7:369-372.

• 摘要

14.  Tey HL, Tan AS, Chan YC. Meta-analysis of randomized, controlled trials comparing griseofulvin and terbinafine in the treatment of tinea capitis. J Am Acad Dermatol. 2011;64:663-670.

• 摘要

15.  Chen X, Jiang X, Yang M, et al. Systemic antifungal therapy for tinea capitis in children. Cochrane Database Syst Rev. 2016;(5):CD004685.

• 全文
• 摘要

16.  Medicines and Healthcare Products Regulatory Agency. Press release: Oral ketoconazole-containing medicines should no longer be used for fungal infections. July 2013. http://www.mhra.gov.uk/ (last accessed 25 October 2015).

• 全文

17.  European Medicines Agency. European Medicines Agency recommends suspension of marketing authorisations for oral ketoconazole. July 2013. http://www.ema.europa.eu/ema/ (last accessed 25 October 2015).

• 全文

18.  US Food & Drug Administration. FDA drug safety communication: FDA warns that prescribing of Nizoral (ketoconazole) oral tablets for unapproved uses including skin and nail infections continues; linked to patient death. May 2016. www.fda.gov (last accessed 6 December 2016).

• 全文

19.  Crawford F, Hollis S. Topical treatments for fungal infections of the skin and nails of the foot. Cochrane Database Syst Rev. 2007;(3):CD001434.

• 摘要

20.  Parish LC, Parish JL, Routh HB, et al. A double-blind, randomized, vehicle-controlled study evaluating the efficacy and safety of naftifine 2% cream in tinea cruris. J Drugs Dermatol. 2011;10:1142-1147.

• 摘要

21.  Parish LC, Parish JL, Routh HB, et al. A randomized, double-blind, vehicle-controlled efficacy and safety study of naftifine 2% cream in the treatment of tinea pedis. J Drugs Dermatol. 2011;10:1282-1288.

• 摘要

22.  El-Gohary M, van Zuuren EJ, Fedorowicz Z, et al. Topical antifungal treatments for tinea cruris and tinea corporis. Cochrane Database Syst Rev. 2014;(8):CD009992.

• 全文
• 摘要

23.  de Sá DC, Lamas AP, Tosti A. Oral therapy for onychomycosis: an evidence-based review. Am J Clin Dermatol. 2014;15:17-36.

• 摘要

24.  Yin Z, Xu J, Luo D. A meta-analysis comparing long-term recurrences of toenail onychomycosis after successful treatment with terbinafine versus itraconazole. J Dermatolog Treat. 2012;23:449-452.

• 摘要

25.  Gupta AK, Fleckman P, Baran R. Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis. J Am Acad Dermatol. 2000;43(suppl 4):S70-S80.

• 摘要

26.  Baran R, Tosti A, Hartmane I, et al. An innovative water-soluble biopolymer improves efficacy of ciclopirox nail lacquer in the management of onychomycosis. J Eur Acad Dermatol Venereol. 2009;23:773-781.

• 摘要

27.  Elewski BE, Rich P, Pollak R, et al. Efinaconazole 10% solution in the treatment of toenail onychomycosis: Two phase III multicenter, randomized, double-blind studies. J Am Acad Dermatol. 2013;68:600-608.

• 摘要

28.  Elewski BE, Aly R, Baldwin SL, et al. Efficacy and safety of tavaborole topical solution, 5%, a novel boron-based antifungal agent, for the treatment of toenail onychomycosis: results from 2 randomized phase-III studies. J Am Acad Dermatol. 2015;73:62-69.

• 全文
• 摘要

29.  Friedlander SF. The optimal therapy for tinea capitis. Pediatr Dermatol. 2000;17:325-326.

• 摘要

30.  Elewski BE. Treatment of tinea capitis: beyond griseofulvin. J Am Acad Dermatol. 1999;40(6 pt 2):S27-S30.

• 摘要

31.  Gonzalez U, Seaton T, Bergus G, et al. Systemic antifungal therapy for tinea capitis in children. Cochrane Database Syst Rev. 2007;(4):CD004685.

• 摘要

32.  Hart R, Bell-Syer SE, Crawford F, et al. Systematic review of topical treatments for fungal infections of the skin and nails of the feet. BMJ. 1999;319:79-82.

• 摘要

33.  Bell-Syer SE, Hart R, Crawford F, et al. A systematic review of oral treatments for fungal infections of the skin of the feet. J Dermatolog Treat. 2001;12:69-74.

• 摘要

34.  Korting HC, Kiencke P, Nelles S, et al. Comparable efficacy and safety of various topical formulations of terbinafine in tinea pedis irrespective of the treatment regimen: results of a meta-analysis. Am J Clin Dermatol. 2007;8:357-364.

• 摘要

35.  Hinojosa JR, Hitchcock K, Rodriguez JE. Clinical inquiries. Which oral antifungal is best for toenail onychomycosis? J Fam Pract. 2007;56:581-582.

• 摘要

36.  Zhang AY, Camp WL, Elewski BE. Advances in topical and systemic antifungals. Dermatol Clin. 2007;25:165-183.

• 摘要

37.  Elewski B, Pollak R, Ashton S, et al. A randomized, placebo- and active-controlled, parallel-group, multicentre, investigator-blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis. Br J Dermatol. 2012;166:389-398.

• 摘要

38.  Elewski B, Pariser D, Rich P, et al. Current and emerging options in the treatment of onychomycosis. Semin Cutan Med Surg. 2013;32(suppl 1):S9-S12.

• 摘要

39.  Menéndez S, Falcón L, Maqueira Y. Therapeutic efficacy of topical OLEOZON® in patients suffering from onychomycosis. Mycoses. 2011;54:e272-e277.

• 摘要

40.  Mordon SR, Betrouni N, Trelles MA, et al. New treatment options for onychomycosis. J Cosmet Laser Ther. 2014;16:306-310.

• 摘要

41.  Landsman AS, Robbins AH. Treatment of mild, moderate, and severe onychomycosis using 870- and 930-nm light exposure: some follow-up observations at 270 days. J Am Podiatr Med Assoc. 2012;102:169-171.

• 摘要

42.  Emtestam L, Kaaman T, Rensfeldt K. Treatment of distal subungual onychomycosis with a topical preparation of urea, propylene glycol and lactic acid: results of a 24-week, double-blind, placebo-controlled study. Mycoses. 2012;55:532-540.

• 摘要

43.  Ribeiro de Souza AL, Kiill CP, Kolenyak dos Santos FK, et al. Nanotechnology-based Drug Delivery Systems for Dermatomycosis Treatment. Curr Nanosci. 2012;8:512-519.

44.  Jahangir M, Hussain I, Ul Hasan M, et al. A double-blind randomized comparative trial of itraconazole versus terbinafine for 2 weeks in tinea capitis. Br J Dermatol. 1998;139:672-674.

• 摘要

45.  Sigurgeirsson B, Olafsson JH, Steinsson JB, et al. Long-term effectiveness of treatment with terbinafine vs. itraconazole in onychomycosis: a 5-year blinded prospective follow-up study. Arch Dermatol. 2002;138:353-357.

• 摘要

46.  Scher RK, Baran R. Onychomycosis in clinical practice: factors contributing to recurrence. Br J Dermatol. 2003;149(suppl 65):5-9.

• 摘要